Climb Bio, Inc.

CLYM

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
SEC CIK: 0001768446

SEC filings (opens in a new tab)

In the last 90 days, Climb Bio, Inc. insiders filed 0 open-market purchases and 1 sale; 108 institutions reported holding it in 13F filings for Q2 2026, worth $734.3M in total; no superinvestor holds it.

Q3 2023 vs. Q2 2023

How the institutions holding Climb Bio, Inc. changed between Q2 2023 and Q3 2023.

All holders in Q3 2023 All holders in Q2 2023

13F holders of CLYM: Q2 2023 compared with Q3 2023
Measure	Q2 2023	Q3 2023	Change
Holders	22	23	+1
Shares	16.7M	16.7M	−1.84K (0.0%)
Value	$46.8M	$44.0M	−$2.85M (−6.1%)

New holders (2)

Institutions that held Climb Bio, Inc. at the end of Q3 2023 but not at the end of Q2 2023.

Institutions new to CLYM in Q3 2023
Institution	Shares	Value	% of portfolio
Qube Research & Technologies Ltd	981	$2.59K	0.00%
UBS Group AG	89	$234	0.00%

Sold out (1)

Institutions that held Climb Bio, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.

Institutions that sold out of CLYM in Q3 2023
Institution	Shares, Q2 2023	Value, Q2 2023
Two Sigma Securities, LLC	14,279	$40.0K